See the latest news and media coverage for Saniona. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing ion channel modulators
saniona.comLast updated
In short: Saniona was named a Gazelle 2026, filed SAN2465's IND, and posted a SEK 60.3M Q2 loss.
Saniona reported a Q2 loss of SEK -58.3 million while securing USD 5 million in value from AstronauTx's option exercise on ATX0926. Management prioritized SAN2668 and SAN2465 for Phase 1 clinical studies.
Saniona receives $5M in AstronauTx shares and up to $172M in potential milestone payments and royalties.
The meeting approved the accounts, re-election of the board and rejection of two proposals due to shareholder opposition.
The company posted a net loss of SEK 46.2 million with SEK 532 million in cash. It continues advancing three CNS programs into Phase 1 trials by late 2026.
Saniona AB has submitted an IND application to the FDA for SAN-2465 for the treatment of major depressive disorder. Pending IND clearance, a phase I...
Saniona AB ( ($SE:SANION) ) has shared an announcement. Saniona AB has called an extraordinary shareholders’ meeting for 2 November 2026 in Malmö to address...
Research company Saniona has completed the toxicological studies and CMC activities necessary ahead of the submission of an IND application for the candidate...
Research company Saniona reports an operating result of minus 60.3 million kronor for the second quarter (-25.9).
Track Saniona and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Saniona and other trending companies.
